Skip to Content

2,441 Results Found

  • Review
  • Open Access
3 Citations
3,130 Views
18 Pages

Adjuvant Treatment for Surgically-Treated Cervical Cancer Patients: A Comprehensive Review

  • Stamatios Petousis,
  • Aristarchos Almperis,
  • Chrysoula Margioula-Siarkou,
  • Frederic Guyon,
  • Vasileios Pergialiotis,
  • Nikolaos Thomakos,
  • Konstantinos Dinas and
  • Alexandros Rodolakis

20 November 2025

Background/Objectives: Cervical cancer (CC) is the fourth most common gynecologic malignancy, disproportionately affecting women in low- and middle-income countries. Despite the effectiveness of HPV vaccination and screening strategies, CC poses a ma...

(This article belongs to the Special Issue Gynecological Cancer: Prevention, Diagnosis, Prognosis and Treatment)
  • Article
  • Open Access
9 Citations
4,086 Views
13 Pages

Impact of the FIGO 2023 Staging System on the Adjuvant Treatment of Endometrial Cancer: A Comparative Analysis with FIGO 2009

  • Federico Ferrari,
  • Elisa Gozzini,
  • Jacopo Conforti,
  • Andrea Giannini,
  • Fabio Barra,
  • Anna Fichera,
  • Filippo Alberto Ferrari,
  • Hooman Soleymani majd and
  • Franco Odicino

10 March 2025

Background: ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) has brought about the publication of the FIGO 2023 staging system with a significant impact in practice for endometrial cancer (EC). Methods: In this comparative study,...

(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
  • Article
  • Open Access
3 Citations
4,621 Views
12 Pages

Survival Comparison of Different Operation Types for Middle Bile Duct Cancer: Bile Duct Resection versus Pancreaticoduodenectomy Considering Complications and Adjuvant Treatment Effects

  • Soo Yeun Lim,
  • Hani Jassim Alramadhan,
  • HyeJeong Jeong,
  • Hochang Chae,
  • Hyeong Seok Kim,
  • So Jeong Yoon,
  • Sang Hyun Shin,
  • In Woong Han,
  • Jin Seok Heo and
  • Hongbeom Kim

10 January 2024

Background: Margin status is one of the most significant prognostic factors after curative surgery for middle bile duct (MBD) cancer. Bile duct resection (BDR) is commonly converted to pancreaticoduodenectomy (PD) to achieve R0 resection. Additionall...

(This article belongs to the Special Issue Clinical Surgery for Hepato-Pancreato-Biliary (HPB) Cancer)
  • Article
  • Open Access
1 Citations
2,144 Views
12 Pages

13 July 2025

Background and Objectives: The common complaints of head and neck cancer patients receiving concurrent chemo-radiotherapy (CCRT) are dry mouth, dysphagia, trismus, hoarseness, sore throat, and oral mucosal damage, which result in retained secretions...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
58 Citations
6,744 Views
26 Pages

Adjuvant Properties of Caffeic Acid in Cancer Treatment

  • Nicole Cortez,
  • Cecilia Villegas,
  • Viviana Burgos,
  • Jaime R. Cabrera-Pardo,
  • Leandro Ortiz,
  • Iván González-Chavarría,
  • Vaderament-A. Nchiozem-Ngnitedem and
  • Cristian Paz

Caffeic acid (CA) is a polyphenol belonging to the phenylpropanoid family, commonly found in plants and vegetables. It was first identified by Hlasiwetz in 1867 as a breakdown product of caffetannic acid. CA is biosynthesized from the amino acids tyr...

(This article belongs to the Special Issue Molecular Studies of Natural Compounds and Plant Extracts—2nd Edition)
  • Review
  • Open Access
34 Citations
2,382 Views
10 Pages

1 November 2019

Background: To date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk strat...

  • Article
  • Open Access
23 Citations
1,567 Views
8 Pages

Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada

  • C. L. Attard,
  • J. A. Maroun,
  • K. Alloul,
  • D. T. Grima and
  • L. M. Bernard

1 February 2010

Objective: The cost-effectiveness of oxaliplatin in combination with 5-fluorouracil/leucovorin (5FU/LV)—the FOLFOX regimen—was compared with that of 5FU/LV alone as adjuvant therapy for patients with stage III colon cancer, from the perspective of th...

  • Systematic Review
  • Open Access
13 Citations
2,975 Views
17 Pages

Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes

  • Raffaello Roesel,
  • Letizia Deantonio,
  • Lorenzo Bernardi,
  • Maria Luisa Garo,
  • Pietro Majno-Hurst,
  • Alberto Vannelli,
  • Marco Cefalì,
  • Maria Celeste Palmarocchi,
  • Maria Carla Valli and
  • Sara De Dosso
  • + 2 authors

19 September 2023

Background: Despite advances in treatment, the prognosis of resectable pancreatic adenocarcinoma remains poor. Neoadjuvant therapy (NAT) has gained great interest in hopes of improving survival. However, the results of available studies based on diff...

(This article belongs to the Collection Recent Advances in Pancreatic Ductal Adenocarcinoma)
  • Article
  • Open Access
9 Citations
4,462 Views
13 Pages

4 May 2021

Despite the effectiveness of primary treatment modalities for cancer, the side effects of treatments, medication resistance, and the deterioration of cachexia after disease progression lead to poor prognosis. A supportive treatment modality to overco...

  • Review
  • Open Access
20 Citations
12,143 Views
13 Pages

11 January 2024

Locally advanced esophageal cancer (LAEC) poses a significant and persistent challenge in terms of effective treatment. Traditionally, the primary strategy for managing LAEC has involved concurrent neoadjuvant chemoradiation followed by surgery. Howe...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
5 Citations
2,738 Views
13 Pages

Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment

  • Asimina Koulouridi,
  • Ippokratis Messaritakis,
  • Emmanouil Theodorakis,
  • Maria Chondrozoumaki,
  • Maria Sfakianaki,
  • Nikolaos Gouvas,
  • John Tsiaoussis,
  • Dimitrios Mavroudis,
  • Maria Tzardi and
  • John Souglakos

15 July 2021

Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiorit...

(This article belongs to the Special Issue Molecular Biomarkers in Colorectal Cancer)
  • Review
  • Open Access
60 Citations
12,419 Views
22 Pages

19 January 2021

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. While there have been significant developments in the treatments for patients with metastatic CRC in recent years, improving outcomes in the adjuvant setting has...

(This article belongs to the Special Issue Adjuvant Chemotherapy for Colorectal Cancer)
  • Feature Paper
  • Article
  • Open Access
5 Citations
4,439 Views
12 Pages

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer

  • Caroline Muñoz,
  • Xiaochen Tai,
  • Jessica Arias,
  • Andrea Eisen,
  • Munaza Chaudhry,
  • Scott Gavura and
  • Kelvin K. W. Chan

21 March 2024

Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Her...

(This article belongs to the Collection New Insights into Breast Cancer Diagnosis and Treatment)
  • Article
  • Open Access
18 Citations
3,238 Views
14 Pages

An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment

  • Gerhard Dyckhoff,
  • Rolf Warta,
  • Christel Herold-Mende,
  • Elisabeth Rudolph,
  • Peter K. Plinkert and
  • Heribert Ramroth

2 February 2021

Supraglottic laryngeal cancer is characterized by poor prognosis. In contrast, excellent outcomes have been published in early-stage supraglottic cancers after laser surgery in single-institutional series in centers of excellence. Are these results r...

(This article belongs to the Special Issue Larynx Cancer: From Diagnosis to Treatment and Rehabilitation)
  • Systematic Review
  • Open Access
14 Citations
4,531 Views
13 Pages

The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis

  • Carlo Ronsini,
  • Stefania Napolitano,
  • Irene Iavarone,
  • Pietro Fumiento,
  • Maria Giovanna Vastarella,
  • Antonella Reino,
  • Rossella Molitierno,
  • Lugi Cobellis,
  • Pasquale De Franciscis and
  • Stefano Cianci

5 March 2024

Endometrial cancer is the most incident gynecological cancer. Lymph node dissemination is one of the most important factors for the patient’s prognosis. Pelvic lymph nodes are the primary site of extra-uterine dissemination in endometrial cance...

(This article belongs to the Section General Surgery)
  • Editorial
  • Open Access
715 Views
2 Pages

1 August 2013

In this issue of Current Oncology, Qin and colleagues from the Sun Yat-sen University Cancer Centre in Guangzhou, China, report their experience using toremifene as adjuvant treatment for 396 premenopausal women with early endocrine-responsive breast...

  • Review
  • Open Access
29 Citations
23,682 Views
18 Pages

Potential of Kalanchoe pinnata as a Cancer Treatment Adjuvant and an Epigenetic Regulator

  • Marta Elena Hernández-Caballero,
  • José Alfredo Sierra-Ramírez,
  • Ricardo Villalobos-Valencia and
  • Emmanuel Seseña-Méndez

29 September 2022

Cancer is a global public health problem that is related to different environmental and lifestyle factors. Although the combination of screening, prevention, and treatment of cancer has resulted in increased patient survival, conventional treatments...

(This article belongs to the Special Issue Cancer Metabolism as a Target for New Oncological Drugs)
  • Review
  • Open Access
149 Citations
17,325 Views
11 Pages

23 March 2021

Adjuvant treatment decisions for endometrial cancer (EC) are based on stage, the histological grade of differentiation, histological subtype, and few histopathological markers. The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE)...

(This article belongs to the Special Issue Radiotherapy in Endometrial Cancer)
  • Article
  • Open Access
1 Citations
1,398 Views
13 Pages

Post-Operative Complications Do Not Influence Time to Adjuvant Treatment in Breast Cancer Patients Undergoing Implant-Based Reconstructions: Pre-Pectoral Versus Sub-Pectoral

  • Gianluca Vanni,
  • Marco Pellicciaro,
  • Marco Materazzo,
  • Alice Bertolo,
  • Amir Sadri,
  • Elisa Campanella,
  • Denisa Eskiu,
  • Ilaria Portarena,
  • Benedetto Longo and
  • Oreste Claudio Buonomo
  • + 1 author

29 December 2025

Background: Immediate breast reconstruction after mastectomy has progressively shifted toward less invasive approaches. The pre-pectoral approach, avoiding muscle dissection, may reduce post-operative pain, surgical trauma, and recovery time. However...

(This article belongs to the Special Issue Breast Cancer: Tailored Rehabilitation Strategies to Address the Challenge of Survivorship Issues)
  • Review
  • Open Access
144 Citations
17,748 Views
29 Pages

Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment

  • Salar Hafez Ghoran,
  • Andrea Calcaterra,
  • Milad Abbasi,
  • Fatemeh Taktaz,
  • Kay Nieselt and
  • Esmaeil Babaei

16 August 2022

Throughout the United States, cancer remains the second leading cause of death. Traditional treatments induce significant medical toxic effects and unpleasant adverse reactions, making them inappropriate for long-term use. Consequently, anticancer-dr...

(This article belongs to the Special Issue The Role of Natural Products in Promoting Well-being: From Foods to Drugs)
  • Review
  • Open Access
50 Citations
6,619 Views
14 Pages

Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review

  • Biagio Barone,
  • Armando Calogero,
  • Luca Scafuri,
  • Matteo Ferro,
  • Giuseppe Lucarelli,
  • Erika Di Zazzo,
  • Enrico Sicignano,
  • Alfonso Falcone,
  • Lorenzo Romano and
  • Felice Crocetto
  • + 5 authors

21 May 2022

Bladder cancer is the ninth most common cancer worldwide. Over 75% of non-muscle invasive cancer patients require conservative local treatment, while the remaining 25% of patients undergo radical cystectomy or radiotherapy. Immune checkpoint inhibito...

(This article belongs to the Special Issue Advances in Immunotherapy for Genitourinary Malignancies)
  • Article
  • Open Access
14 Citations
3,439 Views
13 Pages

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer

  • Christine De Bruyn,
  • Jolien Ceusters,
  • Chiara Landolfo,
  • Thaïs Baert,
  • Gitte Thirion,
  • Sandra Claes,
  • Ann Vankerckhoven,
  • Roxanne Wouters,
  • Dominique Schols and
  • An Coosemans
  • + 2 authors

24 November 2021

In monotherapy, immunotherapy has a poor success rate in ovarian cancer. Upgrading to a successful combinatorial immunotherapy treatment implies knowledge of the immune changes that are induced by chemotherapy and surgery. Methodology: Patients with...

(This article belongs to the Special Issue Immunosuppression in Ovarian Cancer and the Path to Successful Immunotherapy)
  • Review
  • Open Access
8 Citations
4,192 Views
15 Pages

Is There a Place for Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer?

  • Dora Čerina,
  • Tihana Boraska Jelavić,
  • Matea Buljubašić Franić,
  • Krešimir Tomić,
  • Žarko Bajić and
  • Eduard Vrdoljak

23 July 2022

Findings on the efficacy of adjuvant chemotherapy (ACT) of locally advanced cervical cancer (LACC) after the concurrent chemoradiation (CCRT) therapy were inconsistent, and the OUTBACK trial was expected to shed some light regarding the topic. Its re...

  • Article
  • Open Access
20 Citations
3,066 Views
14 Pages

Efficacy of Metformin as Adjuvant Therapy in Metastatic Breast Cancer Treatment

  • Nourhan M. Essa,
  • Heba F. Salem,
  • Marwa O. Elgendy,
  • A. Gabr,
  • Mervat M. Omran,
  • Nivin A. Hassan,
  • Hanaa M. Tashkandi,
  • Steve Harakeh and
  • Marian S. Boshra

20 September 2022

Background: Metformin has been reported to have an anti-tumorigenic impact against metastatic breast cancer (MBC) cells through several mechanisms. Its effect can be evaluated by using many variables such as the response rate (RR) as well as the prog...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
30 Citations
4,391 Views
13 Pages

8 November 2019

The outcome of pancreatic cancer is poor, with a 9% 5-year survival rate. Current treatment recommendations in the 10%–20% of patients who present with resectable disease support upfront resection followed by adjuvant therapy. Until now, only e...

(This article belongs to the Special Issue Current Standards and New Innovative Approaches for Treatment of Pancreatic Cancer)
  • Review
  • Open Access
6 Citations
3,850 Views
25 Pages

3 August 2022

Carotenoids are organic, liposoluble pigments found in nature, which are responsible for the characteristic colors of ripe tomatoes, carrots, peppers, and crustaceans, among others. Palliative care provided to patients with an incurable disease is ai...

(This article belongs to the Special Issue Carotene and Carotenoids and Human Health)
  • Article
  • Open Access
7 Citations
3,632 Views
17 Pages

The Impact of Surgical Treatment with Adjuvant Chemotherapy for Ovarian Cancer on Disorders in the Urinary System and Quality of Life in Women

  • Marcin Opławski,
  • Beniamin Oskar Grabarek,
  • Agata Średnicka,
  • Justyna Czarniecka,
  • Agata Panfil,
  • Zbigniew Kojs and
  • Dariusz Boroń

27 February 2022

Ovarian cancer is the fourth-most-common cause of death among all malignant cancers in women in Poland. This study aimed to compare the functioning of the urinary system and quality of life in women in the 12-month period following the completion of...

(This article belongs to the Special Issue Cancers of the Pelvic Organs: Contemporary Management and Actions for Improving Patients’ Quality of Life)
  • Article
  • Open Access
9 Citations
2,042 Views
18 Pages

Fe3O4@β-cyclodextrin Nanosystem: A Promising Adjuvant Approach in Cancer Treatment

  • Claudia Geanina Watz,
  • Ciprian-Valentin Mihali,
  • Camelia Oprean,
  • Lavinia Krauss Maldea,
  • Calin Adrian Tatu,
  • Mirela Nicolov,
  • Ioan-Ovidiu Sîrbu,
  • Cristina A. Dehelean,
  • Vlad Socoliuc and
  • Elena-Alina Moacă

4 August 2025

The high incidence of melanoma leading to a poor prognosis rate endorses the development of alternative and innovative approaches in the treatment of melanoma. Therefore, the present study aims to develop and characterize, in terms of physicochemical...

(This article belongs to the Special Issue Synthesis of Functional Nanoparticles for Biomedical Applications)
  • Review
  • Open Access
59 Citations
11,459 Views
31 Pages

Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?

  • Erik Osterman,
  • Klara Hammarström,
  • Israa Imam,
  • Emerik Osterlund,
  • Tobias Sjöblom and
  • Bengt Glimelius

9 November 2020

Adjuvant chemotherapy aims at eradicating tumour cells sometimes present after radical surgery for a colorectal cancer (CRC) and thereby diminish the recurrence rate and prolong time to recurrence (TTR). Remaining tumour cells will lead to recurrent...

(This article belongs to the Special Issue Adjuvant Chemotherapy for Colorectal Cancer)
  • Article
  • Open Access
2 Citations
3,117 Views
11 Pages

The “Sandwich” Schedule: A Well-Tolerated Adjuvant Treatment Both in Intermediate–High- and High-Risk Endometrial Cancer

  • Annamaria Ferrero,
  • Luca Fuso,
  • Isabella Cipullo,
  • Roberta Danese,
  • Annalisa Rossi,
  • Sergio Gribaudo,
  • Daniela Attianese,
  • Luca Pace,
  • Saverio Danese and
  • Nicoletta Biglia

26 November 2022

(1) Background: In intermediate–high- and high-risk endometrial cancer (EC), radiotherapy (RT) and chemotherapy (CT) play a basic role. However, there is controversy regarding the optimal timing of their combination. The “sandwich”...

(This article belongs to the Section Gynecologic Oncology)
  • Article
  • Open Access
2 Citations
2,143 Views
19 Pages

18 May 2021

Background: In recent years, great progress has been made in the treatment of breast cancer, but it is still one of the ten leading causes of death in women. The aim of the study was to evaluate the heparanase concentration of invasive breast cancer...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
4 Citations
4,803 Views
15 Pages

Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

  • Goncagul Akdag,
  • Deniz Isik,
  • Akif Dogan,
  • Sedat Yildirim,
  • Oguzcan Kinikoglu,
  • Alper Topal,
  • Sila Oksuz,
  • Ezgi Turkoglu,
  • Heves Surmeli and
  • Nedim Turan
  • + 4 authors

22 August 2024

Background and Objectives: Colorectal cancer (CRC) poses a major global health challenge, with high incidence rates and ongoing treatment debates. Adjuvant chemotherapy benefits for high-risk subgroups, particularly stage II disease, remain controver...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
16 Citations
4,671 Views
14 Pages

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

  • Yu-Hsiang Huang,
  • Pei-Yi Chu,
  • Ji-Lin Chen,
  • Chun-Teng Huang,
  • Chia-Han Lee,
  • Ka-Yi Lau,
  • Wan-Lun Wang,
  • Yu-Ling Wang,
  • Pei-Ju Lien and
  • Chun-Yu Liu
  • + 1 author

28 August 2018

Adjuvant tamoxifen reduces the recurrence rate of estrogen receptor (ER)-positive breast cancer. Previous in vitro studies have suggested that tamoxifen can affect the cancerous inhibitor of protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A...

  • Article
  • Open Access
11 Citations
4,036 Views
11 Pages

Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses

  • Jun Su Park,
  • Jeong Il Yu,
  • Do Hoon Lim,
  • Heerim Nam,
  • Young Il Kim,
  • Jeeyun Lee,
  • Won Ki Kang,
  • Se Hoon Park,
  • Seung Tae Kim and
  • Jae Moon Bae
  • + 5 authors

28 December 2020

We investigated the incidence of renal function impairment after adjuvant treatment for gastric cancer and analyzed the impact of radiotherapy on estimated glomerular filtration rate (eGFR) five years after gastric surgery. We reviewed the medical re...

(This article belongs to the Special Issue Cancer Radiotherapy)
  • Article
  • Open Access
2 Citations
3,986 Views
10 Pages

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

  • Nicola Battelli,
  • Carmela Mocerino,
  • Michele Montedoro,
  • Mirco Pistelli,
  • Ilaria Portarena,
  • Mario Rosanova,
  • Tina Sidoni and
  • Patrizia Vici

Early breast cancer (EBC) treatment has evolved from radical surgery to a multidisciplinary approach, integrating radiotherapy, chemotherapy, targeted therapy, and hormone therapy with surgery to ensure the best possible outcome. Despite these advanc...

(This article belongs to the Section Breast Cancer)
  • Case Report
  • Open Access
11 Citations
4,708 Views
12 Pages

Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation

  • Henning Zelba,
  • Alex McQueeney,
  • Armin Rabsteyn,
  • Oliver Bartsch,
  • Christina Kyzirakos,
  • Simone Kayser,
  • Johannes Harter,
  • Pauline Latzer,
  • Dirk Hadaschik and
  • Saskia Biskup
  • + 2 authors

8 November 2022

Breast cancer is a tumor entity that is one of the leading causes of mortality among women worldwide. Although numerous treatment options are available, current explorations of personalized vaccines have shown potential as promising new treatment opt...

(This article belongs to the Section Vaccination Against Cancer and Chronic Diseases)
  • Article
  • Open Access
40 Citations
6,014 Views
15 Pages

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer

  • Vittoria Basile,
  • Soraya Puglisi,
  • Anna Calabrese,
  • Anna Pia,
  • Paola Perotti,
  • Alfredo Berruti,
  • Giuseppe Reimondo and
  • Massimo Terzolo

14 September 2020

Mitotane is widely used for the treatment of adrenocortical cancer (ACC), although the drug-related toxicity complicates its use. The aim of this study is to assess comprehensively the different endocrine and metabolic unwanted effects of the drug, a...

  • Article
  • Open Access
11 Citations
3,409 Views
16 Pages

Do Breast Cancer Patients Manage to Participate in an Outdoor, Tailored, Physical Activity Program during Adjuvant Breast Cancer Treatment, Independent of Health and Socio-Demographic Characteristics?

  • Ragna Stalsberg,
  • Gro Falkenér Bertheussen,
  • Harriet Børset,
  • Simon Nørskov Thomsen,
  • Anders Husøy,
  • Vidar Gordon Flote,
  • Inger Thune and
  • Steinar Lundgren

5 February 2022

Exercise could reduce the side-effects of adjuvant breast cancer treatment; however, socio-demographic, health, and intervention conditions may affect patients’ adherence to interventions. This study aimed to examine adherence to a 12-month out...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
9 Citations
3,986 Views
27 Pages

20 May 2025

Colorectal cancer (CRC) is the third most common cancer in the world, with increasing incidence and mortality rates. Standard conventional treatments for CRC are surgery, chemotherapy, and radiotherapy. Recently, immunotherapy has been introduced as...

(This article belongs to the Section Autophagy)
  • Article
  • Open Access
9 Citations
1,661 Views
8 Pages

Adjuvant Treatment in Older Patients with Rectal Cancer: A Population-Based Review

  • S. L. Liu,
  • P. O’Brien,
  • Y. Zhao,
  • W. M. Hopman,
  • N. Lamond and
  • R. Ramjeesingh

1 December 2018

Background Little is known about the benefits of adjuvant chemotherapy (adj) in the older population with locally advanced rectal cancer (larc). We evaluated use of adj, survival outcomes, and adj-related toxicity in older patients with larc. Methods...

  • Article
  • Open Access
12 Citations
3,193 Views
10 Pages

Prognostic Role of Tumor Budding in Breast Cancer Patients Receiving Neo-Adjuvant Therapy

  • Paul Mozarowski,
  • Bhubendra Rasaiah,
  • Melissa Reed,
  • Alexis Lewis,
  • Natalie Walde and
  • Ioannis A. Voutsadakis

18 February 2021

Background: Isolated tumor cells or small clusters of tumor cells observed in the vicinity of the main tumor mass in pathology sections, termed tumor budding, are common in cancers and have been associated with prognosis in some settings. This study...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
751 Views
17 Pages

Incidence and Management Trends in Advanced Head and Neck Non-Melanoma Skin Cancer in Ontario

  • Ka-Kit David Yeung,
  • Gregory Pond,
  • Isaac Kong,
  • Han Zhang,
  • Michael Gupta,
  • Zejia Chen and
  • Justin Lee

Head and neck non-melanoma skin cancers (H&N NMSCs) account for most head and neck malignancies. While primary treatment comprises surgery, adjuvant radiation is recommended in advanced tumors. Radiation oncology practice patterns for resected lo...

(This article belongs to the Section Head and Neck Oncology)
  • Review
  • Open Access
16 Citations
5,300 Views
18 Pages

Recent Advances in Perioperative Immunotherapies in Lung Cancer

  • Shota Fukuda,
  • Kenichi Suda,
  • Akira Hamada and
  • Yasuhiro Tsutani

12 September 2023

Several clinical trials have been revolutionizing the perioperative treatment of early-stage non-small cell lung cancer (NSCLC). Many of these clinical trials involve cancer immunotherapies with antibody drugs that block the inhibitory immune checkpo...

(This article belongs to the Collection Recent Advances in Cancer Immunotherapy)
  • Article
  • Open Access
25 Citations
1,174 Views
10 Pages

1 February 2010

Background: This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi–Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (TAC...

  • Article
  • Open Access
5 Citations
3,790 Views
26 Pages

28 April 2023

(1) Background: Cancer treatment, including chemotherapy, endocrine therapy, targeted therapy and radiotherapy, has been identified as an important independent risk factor for venous thromboembolism in cancer patients. The aim of the study was to eva...

(This article belongs to the Special Issue Connections among Obesity, Diabetes, Steroidogenesis and Carcinogenesis)
  • Article
  • Open Access
1 Citations
2,433 Views
13 Pages

Surgical Management and Its Impact on Adjuvant Treatment in Recurrent Ipsilateral Breast Cancer: A Retrospective Cohort Study

  • Ines Torras,
  • Isaac Cebrecos,
  • Helena Castillo,
  • Laura Rodríguez,
  • Pablo Zaragoza-Ballester,
  • Carla Sitges,
  • Ignacio Loinaz,
  • Marta Garcia,
  • Meritxell Molla and
  • Eduard Mension
  • + 1 author

29 August 2024

Background: Breast cancer (BC) recurrence, defined as the reappearance of cancer in the ipsilateral breast after primary treatment, poses significant challenges in clinical management. Despite advances in treatment, recurrence rates persist, ranging...

(This article belongs to the Section Clinical Guidelines)
  • Article
  • Open Access
12 Citations
3,694 Views
11 Pages

Development of a Patient Decision Aid for Rectal Cancer Patients with Clinical Complete Response after Neo-Adjuvant Treatment

  • Lien Smets,
  • Annelies Debucquoy,
  • Eva Oldenburger,
  • Chantal Van Audenhove,
  • Lynn Debrun,
  • Jeroen Dekervel,
  • Gabriele Bislenghi,
  • André D’Hoore,
  • Albert Wolthuis and
  • Karin Haustermans

28 January 2023

Surgery is the primary component of curative treatment for patients with rectal cancer. However, patients with a clinical complete response (cCR) after neo-adjuvant treatment may avoid the morbidity and mortality of radical surgery. An organ-sparing...

(This article belongs to the Special Issue Advances in Radiotherapy and Prognosis of Rectal Cancer)
  • Article
  • Open Access
7,025 Views
13 Pages

Adjuvant Treatment of Stage I–II Serous Endometrial Cancer: A Single Institution 20-Year Experience

  • Aquila Akingbade,
  • François Fabi,
  • Rodrigo Cartes,
  • James Tsui and
  • Joanne Alfieri

29 June 2024

Background: Serous endometrial carcinoma (SEC) is a high-risk subtype of endometrial cancer. The effectiveness of multiple adjuvant therapies, namely chemotherapy (CT), radiotherapy (RT), and sequential/concurrent chemotherapy with radiotherapy (CRT)...

(This article belongs to the Section Gynecologic Oncology)
  • Article
  • Open Access
2 Citations
3,459 Views
10 Pages

7 June 2024

This epidemiological model forecasted reductions in recurrences and recurrence treatment cost savings with adjuvant atezolizumab vs best supportive care among Canadians with stage II-IIIA non-small cell lung cancer (NSCLC) at national and provincial...

(This article belongs to the Topic Cancer Immunity and Immunotherapy: Early Detection, Diagnosis, Systemic Treatments, Novel Biomarkers, and Resistance Mechanisms)

of 49